This page lists the SEC filings reported by Baker Brothers Advisors.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2022-10-07 | BAKER BROS. ADVISORS LP | RHYTHM PHARMACEUTICALS, INC. | 6,062,702 | 10.9% | EDGAR |
| SC 13D/A | 2022-07-20 | BAKER BROS. ADVISORS LP | Immunocore Holdings plc | 4,685,690 | 9.9% | EDGAR |
| SC 13D/A | 2022-06-13 | BAKER BROS. ADVISORS LP | DBV Technologies S.A. | 23,489,669 | 25.0% | EDGAR |
| SC 13D/A | 2022-06-13 | BAKER BROS. ADVISORS LP | Talis Biomedical Corp | 37,497,890 | 66.4% | EDGAR |
| SC 13D/A | 2022-06-06 | BAKER BROS. ADVISORS LP | Kodiak Sciences Inc. | 17,353,846 | 33.4% | EDGAR |
| SC 13D/A | 2022-05-18 | BAKER BROS. ADVISORS LP | Kodiak Sciences Inc. | 16,431,091 | 31.6% | EDGAR |
| SC 13D/A | 2022-05-12 | BAKER BROS. ADVISORS LP | TScan Therapeutics, Inc. | 2,784,792 | 14.7% | EDGAR |
| SC 13D/A | 2022-04-05 | BAKER BROS. ADVISORS LP | IGM Biosciences, Inc. | 3,169,894 | 11.6% | EDGAR |
| SC 13D/A | 2022-03-10 | BAKER BROS. ADVISORS LP | Seagen Inc. | 46,975,613 | 25.6% | EDGAR |
| SC 13D/A | 2022-03-10 | BAKER BROS. ADVISORS LP | INCYTE CORP | 36,269,307 | 16.4% | EDGAR |
| SC 13D/A | 2022-02-14 | BAKER BROS. ADVISORS LP | INCYTE CORP | 34,851,571 | 15.7% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Altimmune, Inc. | 1,941,604 | 4.8% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | AMARIN CORP PLC\UK | 21,169,805 | 5.3% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Ascendis Pharma A/S | 4,541,604 | 8.0% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | HERON THERAPEUTICS, INC. /DE/ | 8,131,678 | 8.0% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Opthea Ltd | 26,427,521 | 7.5% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | BIOCRYST PHARMACEUTICALS INC | 18,386,831 | 9.9% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Verastem, Inc. | 21,491,630 | 11.8% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Mereo Biopharma Group plc | 64,917,601 | 10.0% | EDGAR |
| SC 13G/A | 2022-02-14 | BAKER BROS. ADVISORS LP | Zymeworks Inc. | 4,977,296 | 10.0% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.